Please assess the completion status of the following clinical trial:

Trial Title: Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older;~* Pathological diagnosis of patients with stage II, III A primary NSCLC;~* R0 resection has been accepted;~* Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;~* Informed consent has been signed.~Exclusion Criteria:~* Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.)；~* Patients with unclear pathological types；~* Patients with unclear pathological staging；~* Preserved Shenlingcao Oral Liquid before R0 resection surgery；~* Received immunotherapy or targeted therapy before R0 resection surgery；~* Radiotherapy and chemotherapy before R0 resection surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exposure group (Type: None): Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
- Control group (Type: None): Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).